View ValuationM3 향후 성장Future 기준 점검 2/6M3 (는) 각각 연간 10.9% 및 9.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.핵심 정보10.9%이익 성장률11.45%EPS 성장률Healthcare Services 이익 성장20.1%매출 성장률9.2%향후 자기자본이익률14.16%애널리스트 커버리지Good마지막 업데이트16 Jul 2026최근 향후 성장 업데이트공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.모든 업데이트 보기Recent updates공고 • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026공고 • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • May 01M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.공고 • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026공고 • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026공고 • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.공고 • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025공고 • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.공고 • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025공고 • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares공고 • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.공고 • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.공고 • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.공고 • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €10.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.60 per share.공고 • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €8.75, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €14.82 per share.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €7.45, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €14.26 per share.Reported Earnings • Jul 29First quarter 2025 earnings released: EPS: JP¥16.57 (vs JP¥18.29 in 1Q 2024)First quarter 2025 results: EPS: JP¥16.57 (down from JP¥18.29 in 1Q 2024). Revenue: JP¥64.2b (up 12% from 1Q 2024). Net income: JP¥11.2b (down 9.4% from 1Q 2024). Profit margin: 18% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.공고 • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.공고 • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.Buy Or Sell Opportunity • Apr 25Now 20% overvaluedOver the last 90 days, the stock has fallen 25% to €11.20. The fair value is estimated to be €9.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Board Change • Mar 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.이익 및 매출 성장 예측DB:4YC - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2029472,65367,80365,87086,895103/31/2028429,64660,63960,05578,413133/31/2027392,73454,20252,09164,795133/31/2026351,36349,10058,33270,262N/A12/31/2025343,77449,590N/AN/AN/A9/30/2025330,96645,90153,10464,411N/A6/30/2025306,89141,076N/AN/AN/A3/31/2025284,90040,48442,75251,743N/A12/31/2024265,21541,201N/AN/AN/A9/30/2024247,90739,15949,25555,084N/A6/30/2024245,69644,105N/AN/AN/A3/31/2024238,88345,27150,72958,310N/A12/31/2023234,85246,36348,07459,340N/A9/30/2023233,99748,37448,07458,719N/A6/30/2023231,21849,31549,92459,680N/A3/31/2023230,81849,02849,53657,113N/A12/31/2022229,14546,95549,78754,523N/A9/30/2022223,12847,11754,60958,728N/A6/30/2022218,75260,20349,56553,415N/A3/31/2022208,15963,84548,89152,108N/A12/31/2021199,61767,28046,17848,867N/A9/30/2021191,82363,90044,51746,894N/A6/30/2021180,12347,12445,53147,375N/A3/31/2021169,19837,82244,63846,627N/A12/31/2020158,40431,76038,20540,464N/A9/30/2020144,45026,52031,61734,196N/A6/30/2020135,68523,19026,40529,364N/A3/31/2020130,97321,63523,94926,789N/A12/31/2019125,70421,589N/A26,246N/A9/30/2019121,32920,887N/A19,995N/A6/30/2019116,92719,865N/A19,463N/A3/31/2019113,05919,577N/A17,749N/A12/31/2018109,58519,532N/A13,931N/A9/30/2018104,89719,796N/A16,717N/A6/30/201899,49519,580N/A15,908N/A3/31/201894,47119,684N/A15,913N/A12/31/201790,40218,934N/A16,314N/A9/30/201786,11817,830N/A17,543N/A6/30/201781,96017,303N/A17,382N/A3/31/201778,14316,004N/A16,555N/A12/31/201673,57014,871N/A14,848N/A9/30/201669,00913,526N/A14,631N/A6/30/201667,18912,953N/A13,813N/A3/31/201664,66012,508N/A12,136N/A12/31/201560,28811,664N/A10,106N/A9/30/201557,24110,874N/A9,879N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 4YC 의 연간 예상 수익 증가율(10.9%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 4YC 의 연간 수익(10.9%)이 German 시장(15.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 4YC 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 4YC 의 수익(연간 9.2%)이 German 시장(연간 6.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 4YC 의 수익(연간 9.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 4YC의 자본 수익률은 3년 후 14.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 01:30종가2026/07/23 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스M3, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ritsuo WatanabeBofA Global ResearchLuoxin JiangCitic Securities Co., Ltd.Shuo SongCitic Securities Co., Ltd.18명의 분석가 더 보기
공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.
공고 • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026
공고 • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • May 01M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.
공고 • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026
공고 • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026
공고 • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.
공고 • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
공고 • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.
공고 • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025
공고 • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares
공고 • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.
공고 • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.
공고 • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025
공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.
공고 • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025
Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €10.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.60 per share.
공고 • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €8.75, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €14.82 per share.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €7.45, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €14.26 per share.
Reported Earnings • Jul 29First quarter 2025 earnings released: EPS: JP¥16.57 (vs JP¥18.29 in 1Q 2024)First quarter 2025 results: EPS: JP¥16.57 (down from JP¥18.29 in 1Q 2024). Revenue: JP¥64.2b (up 12% from 1Q 2024). Net income: JP¥11.2b (down 9.4% from 1Q 2024). Profit margin: 18% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
공고 • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024
Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
공고 • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.
Buy Or Sell Opportunity • Apr 25Now 20% overvaluedOver the last 90 days, the stock has fallen 25% to €11.20. The fair value is estimated to be €9.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Board Change • Mar 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.